SENATORS AND INDUSTRY EXPERTS VISITED THE PRODUCTION SITE OF EIRAMED LLP

Continuing preparations for the round table on the topic “State and prospects for the development of the pharmaceutical industry,” today deputies of the Senate of the Parliament of the Republic of Kazakhstan, together with the management of the Unified Distributor, visited the domestic site for the production of medical devices, Eira Med LLP.

The meeting was also attended by representatives of the NPP Atameken, the ALE "Association of Manufacturers of Pharmaceutical and Medical Products FarMedIndustry of Kazakhstan", the Committee for Medical and Pharmaceutical Control of the Ministry of Health of the Republic of Kazakhstan, the Department of Development of the Pharmaceutical and Medical Industry of the Ministry of Health of the Republic of Kazakhstan and NCEM.

«Eira Med is a Kazakh pharmaceutical complex for the production of medical products. First of all, the company’s employees noted the importance of preparing employees for work to move to the cleanroom area. Guests were introduced to the rules and standards of sterility, including the air filtration and access control system.

A system for accounting and monitoring the availability of materials, devices for high-frequency welding, filling zones, the process of gluing units, sterilization, packaging, as well as quality control and protection from contamination were demonstrated. Along with this, visitors are presented with water treatment equipmentand technologies used to ensure high water purity, storage and logistics conditions, quality control and product tracking processes.

The main product of the company is polymer containers for blood and its components, which are produced using high-quality welding technology for polymer materials. Representatives of the pharmaceutical complex noted that the equipment for this technology was purchased in Germany.

Then the parties began discussing current issues related to providing the population with safe, effective and high-quality medicines, as well as the prospects for the development of the pharmaceutical industry.

Particular attention was paid to the development ofdomestic manufacturing. It is known that the Head of State has instructed to intensify cooperation with global pharmaceutical corporations, expand the volume and range of offtake contracts with domestic manufacturers and increase the share of domestically produced medicines and medical devices to 50% by 2025.

The Kazakhstan pharmaceutical industry, thanks to effective government support measures, has enormous potential to reduce import dependence. In the pharmaceutical industry, this is presented in the form of long-term contracts. Over the past 15 years, there has been a systematic increase in the share of Kazakhstani drugs in the procurement of the Unified Distributor, most of which are purchased through long-term contracts.

To date, a long-term contract for the supply of 22 types of medical products has been concluded between the Unified Distributor and Eira Med LLP. The domestic commodity producer intends to continue working to expand the presence of Kazakh products in the CIS countries.

Summing up the meeting, the parties expressed gratitude for the constructive dialogue. It was decided to jointly create favorable conditions for attracting investment and developing infrastructure, which will help increase the competitiveness of Kazakhstani products in the world market. Thanks to the coordinated work of all participants in the pharmaceutical market, state support and international cooperation, Kazakhstan can achieve significant success and ensure sustainable development of the industry.

For reference:

Eira Med LLP is a manufacturing enterprise specializing in the production of medical products for the blood service. The total production capacity of EiraMed LLP is 400 thousand products per year, and the actual capacity is 244,214 products per year (64%). The full-time staff of the companyis152employees.